

Confidence in the Data

Redefining radiation safety in the cath lab.

By Karim Al-Azizi, MD

As interventionalists, we constantly make high-stakes decisions about devices, access, strategy, etc., all in the name of improving patient outcomes. These decisions are guided by data, clinical evidence, and experience. Radiation protection should be no different. The same level of clinical scrutiny we apply to patient care must extend to how we protect ourselves and our teams. The future of radiation depends on evidence-based solutions. And as with anything else in our field, the data should lead.

THE DATA

The Rampart system (Rampart) distinguishes itself with rigorous clinical validation. Among six published studies to date, two stand out—“Radiation Exposure Using Rampart vs Standard Lead Aprons and Shields During Invasive Cardiovascular Procedures” and “Real-World Reductions in Lead-Free Radiation Exposure With the Rampart System During Endovascular Procedures.”^{1,2}

The results are not just measurable but also clinically significant. Rampart consistently demonstrates substantial




Figure 1. Rampart reduced total body radiation by > 99% compared to traditional lead aprons and shields. Adapted with permission from Lisko JC, Shekiladze N, Chamoun J, et al. Radiation exposure using Rampart vs standard lead aprons and shields during invasive cardiovascular procedures. J Soc Cardiovasc Angiogr Interv. 2023;3:101184.

TABLE 1. RAMPART RADIATION EXPOSURE REDUCTION PER PROCEDURE

1,712 procedures from 671 operators at 153 sites (19% OUS) - Median fluoroscopy time 7.7 min (IQR, 3.9-15.3 min) - Average reduction of 99%+, regardless of procedure type	Procedure	Control (mGy)	Main Operator (mGy)	Radiation Reduction (%)
	All (N = 1,712)	0.955	0.002	99.8
	Coronary procedure (n = 1,340)	1.030	0.002	99.8
	Diagnostic angiogram (n = 750)	0.643	0.002	99.7
	Non-CTO PCI (n = 474)	1.80	0.003	99.8
	CTO PCI (n = 115)	2.92	0.008	99.8
	Peripheral (n = 27)	0.298	< 0.001	100.0
	Structural (n = 139)	0.923	0.001	99.9
	Electrophysiology (n = 68)	0.300	< 0.001	100.0

Note: Results are presented as median values.

Abbreviations: CTO, chronic total occlusion; mGy, milligray; OUS, outside the United States; PCI, percutaneous coronary intervention.

Data from Herzig MS, Kochar A, Hermiller JB, et al. Real-world reductions in lead-free radiation exposure with the Rampart system during endovascular procedures. *Am J Cardiol.* 2025;243:59-64. doi: 10.1016/j.amjcard.2025.02.019

TABLE 2. EARLY FIELD DATA FOR RAMPART GUARDIAN COMPARED TO RAMPART DEFENDER

Parameter	Emory RCT ¹	Real-World Study ²	Guardian LMR*
Product	Defender	Defender	Guardian
Number of sites	1	153 (125 United States, 28 international)	11
Number of operators	9	671	28
Number of cases	47	1,713	156
Procedure types	Coronary (PCI, CTO PCI), structural, EP	Coronary (diagnostic angiography, PCI, CTO PCI), structural, EP, peripheral, EVAR	Coronary/structural, peripheral/vascular
Median fluoroscopy time	12.3 min	7.7 min	13.8 min
Median radiation dose (control)	38.8 mRem	95.2 mRem	140.7 mRem
Radiation reduction compared to LAS	99+%	99+%	99+%
Median operator one radiation dose	0.1 mRem	0.2 mRem	0.2 mRem
Median operator two radiation dose	0.1 mRem	0.1 mRem	0.06 mRem

Abbreviations: CTO, chronic total occlusion; EP, electrophysiology; EVAR, endovascular aneurysm repair; LMR, limited market release; mRem, millirem; LAS, lead apron and shield; PCI, percutaneous coronary intervention; RCT, randomized controlled trial. *Data on file

reductions in radiation exposure across both controlled trials and real-world procedures, without compromising workflow or access.

In the randomized controlled trial (RCT) conducted at Emory University School of Medicine, 100 consecutive cases were assigned to either standard lead aprons and shields or Rampart shielding without the use of lead aprons. Using real-time dosimetry across eight anatomical points, the results were striking:

- Rampart provided 99.7% radiation attenuation, resulting in 20 times more total body protection than traditional lead aprons and shields (Figure 1).¹
- Fluoroscopy time and procedural access were

unaffected, confirming the system's practical compatibility with coronary and structural heart interventions.¹

Yet RCTs are just one piece of the puzzle. In practice, variability prevails—case complexity, operator technique, and cath lab layout all impact radiation exposure to staff. That is why the “**Real-World Reductions in Lead-Free Radiation Exposure With the Rampart System During Endovascular Procedures**” study, recently published in *American Journal of Cardiology* and including > **1,700 procedures across 153 sites**, is so important.² It demonstrated consistent, lead apron-free radiation protection in coronary, structural, peripheral, and emergency cases. Median operator radiation was just **0.2 mRem**, a level comparable to or

The Radiation Safety Revolution: The Next Generation of Interventional Team Protection

Sponsored by Rampart

lower than traditional underlead dosimetry but achieved without the physical burden of wearing lead aprons. This held true across access sites (radial, femoral, combined) and was remarkably stable even with complex chronic total occlusion cases (Table 1).²

Rampart's strength lies in the balance between these two studies—one strictly controlled, the other completely practical. Regardless of case complexity, geography, or type of procedure, the outcomes are consistent: **significant radiation reduction without the weight of lead aprons.**

Although the published data have focused primarily on the Defender system (Rampart), early field data for Rampart's **Guardian** system are equally promising. Across **11 sites, 28 operators, and 156 procedures**, the median exposure for operator one was **0.2 mRem**, while operator two's exposure was **0.06 mRem**. These cases spanned coronary, structural, and peripheral interventions, supporting the consistent performance of the Rampart platform across product lines (Table 2).¹⁻³

Overall, the safety of operators and staff is a priority; it is a work hazard that has to be taken very seriously, and systems like Rampart address two main issues: radiation attenuation and alleviating the physical burden of lead.

SUMMARY

Radiation protection is no longer a guessing game. With Rampart, there are data to practice safely and the flexibility to practice freely. In an era when operator wellness, team safety, and procedural efficiency are under increasing pressure, Rampart delivers what few solutions can: **evidence-based confidence to practice without lead aprons.** ■

1. Lisko JC, Shekiladze N, Chamoun J, et al. Radiation exposure using Rampart vs standard lead aprons and shields during invasive cardiovascular procedures. *J Soc Cardiovasc Angiogr Interv.* 2023;3:101184. doi: 10.1016/j.jscvi.2023.101184

2. Herzig MS, Kochar A, Hermiller JB, et al. Real-world reductions in lead-free radiation exposure with the Rampart system during endovascular procedures. *Am J Cardiol.* 2025;243:59-64. doi: 10.1016/j.amjcard.2025.02.019

3. Rampart data on file.



Karim Al-Azizi, MD

Medical Director, Cardiac
Catheterization Laboratories
Baylor Scott & White Health—
The Heart Hospital Plano
Plano, Texas
Disclosures: None.